Role of LSD1 in Hypertension and Renal Injury in Blacks

LSD1 在黑人高血压和肾损伤中的作用

• 批准号: 10686277
• 负责人: Andrea Haas
• 金额: $ 19.26万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2026-09-14
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10686277
• 关键词: Address; Advisory Committees; Affect; Albumins; Albuminuria; Alleles; Amlodipine; Antihypertensive Agents; Basic Science; Biological Assay; Black Populations; Black race; Blood Pressure; Calcium Channel; Cardiovascular system; Chronic Kidney Failure; Clinical; Clinical Data; Clinical Trials Design; Collection; Creatinine; Cross-Sectional Studies; Data; Databases; Dedications; Development; Diet; Disease; Doctor of Philosophy; Double-Blind Method; Endocrinology; Enrollment; Epigenetic Process; Essential Hypertension; Exhibits; Functional disorder; Future; Genes; Genetic Carriers; Genetic Markers; Genetic Polymorphism; Genetic Transcription; Goals; Heart Diseases; High Prevalence; Human; Hypertension; Individual; Injury to Kidney; International; Investigation; KDM1A gene; Kidney; Knowledge; Learning; Longitudinal Studies; Mediating; Mentors; Mentorship; Methodology; Mineralocorticoid Receptor; Mus; Outcome; Outpatients; Participant; Pharmaceutical Preparations; Physicians; Physiological; Physiology; Population; Prevalence; Public Health Schools; Randomized; Regulator Genes; Research; Research Personnel; Research Proposals; Risk; Role; Running; Sampling; Secondary to; Sodium; Statistical Data Interpretation; Stroke; Techniques; Testing; Training; Translational Research; Tubular formation; United States; Urine; Variant; Visit; Wild Type Mouse; Work; antagonist; black/white disparity; blood pressure control; blood pressure elevation; blood pressure reduction; blood pressure regulation; cardiovascular effects; career; cohort; comorbidity; drug efficacy; eplerenone; health disparity; hypertension control; hypertensive; hypertensives; improved; novel strategies; patient oriented; pre-clinical; precision medicine; primary outcome; rat KIM-1 protein; renal damage; risk variant; salt sensitive; secondary outcome; side effect; skills; statistics; tool; treatment program; urinary

PROJECT SUMMARY/ABSTRACT This translational research proposal focuses on lysine-specific demethylase 1 (LSD1), an epigenetic regulator of gene transcription. The project’s overall aim is to show that polymorphisms in LSD1 (rs587168) are involved in blood pressure regulation and the pathophysiology of renal injury in Blacks, and that excess mineralocorticoid receptor activity mediates these effects. The applicant will address this hypothesis using a database approach (Aim 1) and a physiology-directed study in Black hypertensives (Aim 2). Specific Aim 1 will determine whether Black LSD1 risk allele carriers have greater evidence of renal damage (albuminuria) than non-risk allele carriers. The applicant will perform a cross-sectional study in 180 hypertensive Blacks (90 risk and 90 non-risk LSD1 allele carriers) from the International Hypertension Pathotype Cohort (HyperPATH) to assess whether urine albumin/creatinine levels (marker of renal glomerular and tubular damage) and Kidney Injury Molecule-1 (marker of renal tubular damage) are higher in Black LSD1 risk allele carriers vs non-risk allele carriers. Specific Aim 2 is a proof-of-principle physiologic study in hypertensive Black LSD1 risk allele carriers testing the hypothesis that reductions in blood pressure will be greater with a genetically-driven anti-hypertensive approach (mineralocorticoid receptor antagonist, eplerenone) compared to a non-specific approach (amlodipine). 56 participants will be enrolled in a 12-week randomized, double-blind, active controlled, outpatient study to assess whether eplerenone (LSD1 specific treatment) proves superior in 24-hr ambulatory systolic blood pressure reduction than amlodipine (non-specific treatment). If Aim1 is positive, the applicant will also assess change in urine albumin and KIM-1 levels in the longitudinal study. Successful completion of these Aims will document whether a genetic marker, LSD1, identifies Black individuals whose blood pressure is uniquely responsive to mineralocorticoid receptor blockade--personalized, precision medicine. Further, results of this project have the potential to reduce Black-White disparities in health outcomes secondary to poor blood pressure control. The training plan includes dedicated mentorship by Gordon Williams, MD (Mentor) and Gail Adler, MD, PhD (co- Mentor), international experts in the field of cardiovascular endocrinology. In addition to Drs. Williams and Adler, the applicant will have an advisory team composed of Bernard Rosner, PhD (statistician), Joseph Bonventre, MD, PhD (nephrologist), and Herman Taylor, MD (cardiologist), each offering expertise tailored to the applicant’s needs and goals. Also, the applicant will complete formal training in clinical/translational investigation, clinical trial design, and statistics at the Harvard T.H. Chan School of Public Health. These activities will provide the applicant with the necessary tools critical for development toward her goal of becoming an independent patient- oriented investigator in the field of cardiovascular endocrinology.

项目总结/文摘